◀ Back to CDKN1A
BCR — CDKN1A
Text-mined interactions from Literome
Keeshan et al., Leukemia 2001
:
Despite the drug-resistant phenotype, high
Bcr-Abl levels concomitantly
increased the expression of p53,
p21 , Bax and down-regulated Bcl-2
Pierce et al., Hematol J 2001
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive) :
This enhanced
BCR/ABL mediated growth inhibition occurred over a range of growth factor concentrations and was
independent of changes in
p21 ( Cip1 ) and p27 ( Kip ) levels
Keeshan et al., Br J Haematol 2003
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive) :
Bcr-Abl upregulates cytosolic
p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K) independent pathway
Rangatia et al., Leukemia 2006
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive) :
Lack of
BCR-ABL leads to cell cycle arrest in G1 phase as observed by decrease in cyclin D1 and
increase in
p21 and p27 cdk inhibitors mRNA